Lyell Immunopharma
Lyell Immunopharma raises $425M Series C at $1.4B valuation
Lyell Immunopharma: Series C Funding Round
Lyell Immunopharma has successfully raised $425M in Series C funding, reaching a valuation of $1.4B.
Company Overview
T-cell reprogramming for solid tumors
Funding Details
The Series C round was led by GV, with participation from F-Prime Capital, Bain Capital Life Sciences, Patient Square Capital, Bristol Myers Squibb.
Company Information
- Headquarters: 201 Haskins Way, South San Francisco, CA 94080
- Founded: 2018
- Employees: 300+
- Category: Biotech
Investment
Lyell Immunopharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- GV: Verified investor in Series C
- F-Prime Capital: Verified investor in Series C
- Bain Capital Life Sciences: Verified investor in Series C
- Patient Square Capital: Verified investor in Series C
- Bristol Myers Squibb: Verified investor in Series C
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free